HEALTH TRAIN EXPRESS Mission: To promulgate health education across the internet: Follow or subscribe to Health Train Express as well as Digital Health Space for all the updates for health policy, reform, public health issues. Health Train Express is published several times a week.Subscribe and receive an email alert each time it is published. Health Train Express has been published since 2006.
Tuesday, August 20, 2024
More Than Half of IRA Negotiation Savings to Come From Three Drugs:
Monday, August 19, 2024
Medicare has negotiated price cuts for 10 Drugs
CMS (Medicare) controls a large part of the pharmaceuticals used by patients and they have considerable influence on pharma.
Medicare beneficiaries will benefit by price reductions for drugs intended for patients with common diseases, such as diabetes, heart failure, psoriasis, ulcerative colitis, blood clotting disorders, and blood cancers
The discounts are considerable ranging from 79%% to 36%
Here’s the list:
Januvia: Manufactured by Merck Sharp Dohme to treat diabetes, the negotiated price is $113 for a 30-day supply, which is a 79% reduction
Fiasp (insulin} FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill: Manufactured by Novo Nordisk to treat diabetes, the negotiated price is $119 for a 30- day supply, which is a 76% reduction.
Farxiga: Manufactured by AstraZeneca AB to treat diabetes, heart failure and chronic kidney disease, the negotiated price is $178.50 for a 30-day supply, a reduction of 68%.
Enbrel: Manufactured by Immunex Corp. to treat rheumatoid arthritis, psoriasis and psoriatic arthritis, the negotiated price is $2,355 for a 30-day supply, which is a 67% cut.
Jardiance: Manufactured by Boehringer Ingelheim to treat diabetes, heart failure and chronic kidney disease, the negotiated price is $197 for a 30-day supply, which is a 66% savings.
Stelara: Manufactured by Janssen Biotech Inc. to treat Psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis, the negotiated price is $4,695 for a 30-day supply, which is a 66% reduction.
Xarelto: Manufactured by Janssen Pharms for prevention and treatment of blood clots, and reduction of risk for patients with coronary or peripheral artery disease, the negotiated price is $197 for a 30-day supply. It’s a 62% reduction
Eliquis: Manufactured by Bristol Myers Squibb for prevention and treatment of blood clots, the negotiated price is $231 for a 30-day supply, reduction of 56%
Entresto: Manufactured by Novartis Pharms Corp to treat heart failure, the negotiated price is $295 for a 30-day supply, which is a 53% reduction.
Imbruvica: Manufactured by Pharmacyclics LLC to treat blood cancers, the negotiated price is $9,319 for a 30-day supply, which is a 38% cut.
These drugs are heavily marketed by the media on television and cable television.
Patient awareness causes them to ask for these drugs from physicians. The fact that there have been significant reductions in prices will increase patient demand.
Whatever price reductions the increase in demand will offset the reduction in price.
Thursday, August 15, 2024
Private Equity Ownership of Medical Practice and Hospital Ownership and What it does to the Health Care System
Key Points
- During the first half of 2024, nine private equity-owned healthcare companies have filed for bankruptcy, comprising 23% of all large US healthcare bankruptcies so far this year.
- Some other private equity-owned healthcare companies have also defaulted on their debt but avoided bankruptcy court through distressed debt exchanges. At least six major healthcare companies have completed distressed exchanges this year.
- Many more private equity-owned healthcare companies are highly leveraged and considered at high risk for bankruptcy, including multiple companies that have taken on debt to finance payouts to their private equity owners.
Private equity firms, which characteristically use excessive debt and aggressive financial strategies, are key drivers in a recent wave of healthcare bankruptcies in the US, threatening the stability of essential healthcare services across the country.
In our April report, PESP found that at least 17 (21%) of the 80 large healthcare companies that filed for bankruptcy last year were owned by private equity firms.
This trend has continue in 2024. In the first six months of this year, PESP has tracked at least nine bankruptcies by companies that were private equity-owned, which accounts for 23% of all healthcare bankruptcies filed this year.
On top of that, there have been at least six more defaults by PE-owned healthcare companies (where the companies managed to restructure their debt outside of bankruptcy court).
The rise in healthcare bankruptcies, and bankruptcies by private equity-owned healthcare companies in particular, stems from a few factors. Private equity firms routinely use much higher levels of debt than other companies, often the result of leveraged buyouts and aggressive debt-funded growth strategies.
Private equity owns or recently owned companies that accounted for three of the four largest healthcare bankruptcies of the year so far, where the companies’ total liabilities exceeded $1 billion: Consulate Health Care, Steward Health Care, and Cano Health.[13]
Not included in that list is Careismatic Brands, a medical scrubs manufacturer owned by Partners Group that also had a >$1 billion bankruptcy,[14] but is classified within the consumer discretionary market rather than healthcare.[15]
Some private equity firms even add additional debt to their portfolio companies to fund shareholder payouts, known as “dividend recapitalizations.” Just last month, private equity-owned medical debt collector Ensemble RCM took out an over $800 million loan to finance a payout to its private equity owners.[1]
Private equity’s aggressive use of debt leaves companies more vulnerable to changing market conditions, including high interest rates and rising labor costs.
Private Equity Bankruptcy Trend Has Continued in 2024
Of the 40 large healthcare companies that have filed for bankruptcy so far this year (January-June 2024), nine companies are or were recently backed by private equity, accounting for 23% of the total filings.[2]
Most of the bankruptcies are filed as Chapter 11, which allows for a financial reorganization over time to allow the PE to survive. However many PEs in Chapter 11 proceed to Chapter 7 (a complete liquidation of all assets) In any case the entity is in the hands of a trustee who will make decisions on the PE's ability to meet the Chapter 11 bankruptcy or proceed to a Chapter 7 liquidation
To make matters worse PEs often borrow to pay shareholder dividends, to eliminate shareholder exits.
Any entity considering relief from a private entity should evaluate the buyer, its track record, financial statements, and history of previous acquisitions.
The makeup of PEs varies, from larger Venture Capital investors to smaller non-financial firms. Firms may include individual hospitals, clinics, or smaller groups of interested competitors.. This group may include competitors who want to increase their market share to improve their value to insurers by expanding their coverage area.
Physician Involvement
Neophyte physicians should examine the financial health of their proposed employer. They must avoid distressed entities such as group practices clinics and hospitals. Should the entity file for Chapter 7 many physicians could face loss of income and a forced move. Non-partners face the risk of termination, while partners may face liabilities for Chapter 7. This is good. reason for having a personal Chapter S to shield themselves from personal liability.
Tuesday, August 13, 2024
Which strains of tuberculosis are the most in | EurekAlert!
At a glance:
Highly localized TB strains are less infectious in cosmopolitan cities and more likely to infect people from the geographic area that is the strain’s natural habitat.
The findings offer new clues for tailoring preventive treatments after exposure to TB based on strain-host affinity.
The research provides the first controlled evidence that TB strains may evolve with their human hosts, adapting to be more infectious to specific populations.
For some forms of tuberculosis, the chances that an exposed person will get infected depend on whether the individual and the bacteria share a hometown, according to a new study comparing how different strains move through mixed populations in cosmopolitan cities.
Results of the research, led by Harvard Medical School scientists and published Aug. 1 in Nature Microbiology, provide the first hard evidence of long-standing observations that have led scientists to suspect that pathogen, place, and human host collide in a distinctive interplay that influences infection risk and fuels differences in susceptibility to infection.
The findings may also help inform new prevention and treatment approaches for tuberculosis, a wily pathogen that, each year, sickens more than 10 million people and causes more than a million deaths worldwide, according to the World Health Organization.
Where widespread Haarlem strains are prevalent
In these nations, at least 10 percent of the strains in a multinational database of tuberculosis genotypes were from the globally distributed Haarlem sublineage of Lineage 4, a group of TB varieties known as the Euro-American lineage that is prevalent around the world.
The analysis showed that close household contacts of people diagnosed with a strain of TB from a geographically restricted lineage had a 14 percent lower rate of infection and a 45 percent lower rate of developing active TB disease compared with those exposed to a strain belonging to a widespread lineage.
The study also showed that strains with narrow geographic ranges are much more likely to infect people with roots in the bacteria’s native geographic region than people from outside the region.
The researchers found that the odds of infection dropped by 38 percent when a contact is exposed to a restricted pathogen from a geographic region that doesn’t match the person’s background, compared with when a person is exposed to a geographically restricted microbe from a region that does match their home country. This was true for people who had lived in the region themselves and for people whose two parents could each trace their heritage to the region.
This pathogen-host affinity points to a shared evolution between humans and microbes with certain biological features rendering both more compatible and fueling the risk for infection, the researchers said.
“The size of the effect is surprisingly large,” said Maha Farhat, the Gilbert S. Omenn, MD ’65, PhD Associate Professor of Biomedical Informatics in the Blavatnik Institute at HMS. “That’s a good indicator that the impact on public health is substantial.”
Why differences matter
Thanks to the growing use of genetic sequencing, researchers have observed not all circulating strains are created equal. Some lineages are widespread and responsible for much of the TB around the world, while others are prevalent only in a few restricted areas. Given that the complex nature of TB transmission in high-incidence settings where people often have multiple exposures to different lineages, researchers have not been able to compare strains under similar conditions and have been left to speculate about possible explanations for the differences between strains.
Many factors increase the risk of contracting tuberculosis from a close contact. One of the best predictors of whether a person will infect their close contacts is bacterial load, measured by a test called sputum smear microscopy, which shows how many bacteria a person carries in their respiratory system.
However the new study showed that for geographically restricted strains, whether a person has ancestors who lived where the strain is common was an even bigger predictor of infection risk than bacterial load in the sputum. In the cases analyzed in the study, this risk of common ancestry even outweighed the risk stemming from having diabetes and other chronic diseases previously shown to render people more susceptible to infection.
The findings add to a growing body of evidence of the importance of paying attention to the wide variation between different lineages of tuberculosis and to the details of how different lineages of tuberculosis interact with different host populations.
Previous studies have shown that some genetic groups of TB are more prone to developing drug resistance and that TB vaccines appear to work better in some places than others. There is also evidence that some treatment regimens might be better suited to some strains of TB than others.
“These findings emphasize how important it is to understand what makes different strains of TB behave so differently from one another, and why some strains have such a close affinity for specific, related groups of people,” said Matthias Groeschel, research fellow in biomedical informatics in Farhat’s lab at HMS; resident physician at Charité, a university hospital in Berlin; and the study’s first author.
In addition to the analysis of clinical, genomic, and public health data, the researchers also tested the ability of different strains of TB to infect human macrophages, a type of immune cell that TB hijacks to cause infection and disease. The researchers grew cells from donors from different regions. Once again, cell lines from people with ancestry that matched the native habitat of a restricted strain of tuberculosis bacteria were more susceptible to the germs than cells from people from outside the area, mirroring the results of their epidemiologic study.
Until now, most experiments of the interaction between human immune cells and TB have not compared how TB interacts with cells of hosts from different populations or places, the researchers said.
While this experiment was not designed to capture insights about the mechanism underlying the affinity between human and TB populations sharing geographic backgrounds, it highlights the importance of using multiple strains of TB and cells from diverse populations to inform treatment and prevention. It also points to the need for more basic research to understand the genomic and structural differences in how bacterial and host cells interface, the researchers said.
Monday, August 12, 2024
Health Care is in a death spiral
Death Spiral
1. Doctor Shortage, early retirement, or change to a nonclinical career. Boomer bulge. Incoming new doctors often get MBAs and go to non-clinical careers in IT, or AI.
2. Nurse shortage. Early dropout.
3. Hospital bed shortage
4. Continuing inflation at 8% / year
Monday, August 5, 2024
The Early Preveniton of Alzheimer's Diseae
1. New research suggests that Alzheimer's disease may be reversible through lifestyle changes, including:
- Adopting a plant-based diet
- Engaging in regular exercise, including strength training
- Practicing meditation or yoga
- Increasing social engagement
2. The research study followed 51 adults in their 70s with mild cognitive impairment or early Alzheimer's. The group that made the lifestyle changes showed significant improvements, with 70% either stabilizing or markedly improving their cognitive function.
3. Examples of improvements seen in the study participants include:
- Resumed ability to read, play music, manage affairs, and follow complex movie plots
- Reversal of symptoms in a participant named Cici Zerbe, who made lifestyle changes after the study ended
4. Experts like Dr. Dean Ornish and Dr. Richard Isaacson recommend the following for brain health and Alzheimer's prevention:
- Eating a mostly plant-based diet
- Exercising regularly, including brisk walking with a weighted belt
- Managing blood sugar levels
- Maintaining mental stimulation and social engagement
5. The article highlights the personal experiences of Dr. Ornish and Dr. Gupta, who have had family members affected by Alzheimer's, and their motivation to explore lifestyle-based approaches to prevention and treatment.
In summary, the research suggests that Alzheimer's disease may be reversible through a combination of dietary, exercise, and lifestyle changes, providing hope for those affected by the disease.
'If Walmart can't do it … how can the average physician survive?': Independent practices becoming less feasible
"The proposed CMS pay cut for physicians can have significant implications across the healthcare system," Ernest Braxton, MD, spine and neurological surgery specialist at Vail-Summit Orthopaedics and Neurosurgery, told Becker's. "CMS efforts to control costs will have unintended consequences on physician workforce morale, patient care quality, and healthcare access. This will be the last straw for many private practice physicians. We will see more early retirements and a large number of physicians opting out of Medicare in order to create private pay contracts with patients for non-urgent/emergency care — shifting the economic burden to healthcare consumers."
Many feel the pressure to remain financially feasible weighs on healthcare success.
Survival
We talk a lot about fixing healthcare, but none of it matters if the people delivering care cannot survive the system themselves. More than ...
-
David’s Health Tech Newsletter: No. 62 – “Companies Disrupting Healthcare In 2015” via reddit.com The 21st Century has shown rapid develo...
-
(click for locations) Or is it Doctor Google ? Either you are a lover or a hater of all things Google. Google however has some thing...
-
At the intersection of health, health care, and policy.At the intersection of health, health care, and policy. A Four Years Into A C...


